KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Capital Expenditures (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Capital Expenditures for 9 consecutive years, with $143000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Capital Expenditures fell 39.15% year-over-year to $143000.0, compared with a TTM value of $1.0 million through Mar 2025, up 1276.0%, and an annual FY2025 reading of $608000.0, down 45.91% over the prior year.
  • Capital Expenditures was $143000.0 for Q1 2025 at Biocryst Pharmaceuticals, down from $675000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $987000.0 in Q3 2023 and bottomed at -$1.6 million in Q4 2023.
  • Average Capital Expenditures over 3 years is $140777.8, with a median of $160000.0 recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 141.82% in 2024, while the deepest fall reached 94.02% in 2024.
  • Year by year, Capital Expenditures stood at -$1.6 million in 2023, then soared by 141.82% to $675000.0 in 2024, then crashed by 78.81% to $143000.0 in 2025.
  • Business Quant data shows Capital Expenditures for BCRX at $143000.0 in Q1 2025, $675000.0 in Q4 2024, and $59000.0 in Q3 2024.